Abstract 1706P
Background
We assessed the occurrence of febrile neutropenia (FN) events and the associated healthcare resource use and costs of cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim (PEG) versus lipegfilgrastim (LI-PEG).
Methods
A retrospective analysis was conducted using a German insurance claims database. Adults receiving chemotherapy with a prescription code for PEG (n=734) or LI-PEG (n=346) between 2016-2017 were observed over a 1-year follow-up period. Patient subgroups were analysed according to cancer type (all types, breast, lung, lymphomas, neoplasms of the colon, pancreas, or stomach) and FN risk (overall, intermediate, high). FN risk was determined by a clinical expert by assessing the patients’ chemotherapy regimen received within the first 30 days of treatment. Outcomes were adjusted via regression analysis.
Results
In the PEG and LI-PEG groups, 30% (n=220) and 34% (n=119) of patients had intermediate FN risk, and 70% (n=514) and 66% (n=227) had high FN risk, respectively. The majority were female (PEG 77%; LI-PEG 80%) with a mean age of 58.2 years and 58.0 years. Across all cancer types during follow-up, 4.4% and 3.5% of patients receiving PEG or LI-PEG experienced a FN event. There were no significant differences in the mean numbers of FN events per patient for PEG (0.05) versus LI-PEG (0.04) across all cancer types. Annual mean neutropenia-related healthcare costs during follow-up were €603.61 and €441.35 for the PEG and LI-PEG groups; among patients with lymphomas, these costs were significantly greater (p=0.03) with PEG (€1,611.85) versus LI-PEG (€381.80). All-cause hospitalisations were significantly (p<0.01) higher for lymphoma patients receiving PEG (2.76) versus LI-PEG (1.60). The occurrence of adjusted neutropenia-related hospitalisations was significantly (p=0.02) higher for lymphomas than breast cancer (exponentiated coefficient [95% confidence interval]: 2.82 [1.16; 6.97]).
Conclusions
Unadjusted neutropenia-related healthcare costs and all-cause hospitalisations were significantly higher for lymphoma patients treated with PEG versus LI-PEG.
Clinical trial identification
Editorial acknowledgement
We would like to thank Samuel Bestall and Inspired Science for their support in writting this abstract.
Legal entity responsible for the study
The authors.
Funding
TEVA Pharmaceuticals Ltd.
Disclosure
H. Link: Financial Interests, Personal and Institutional, Invited Speaker: Accord; Financial Interests, Personal and Institutional, Invited Speaker: Amgen; Financial Interests, Personal and Institutional, Invited Speaker: G1 Therapeutics; Financial Interests, Personal and Institutional, Invited Speaker: Hexal - Sandoz Novartis; Financial Interests, Institutional, Invited Speaker: Molecular Health; Financial Interests, Personal and Institutional, Invited Speaker: SAP COPE Program; Financial Interests, Personal and Institutional, Invited Speaker: Servier; Financial Interests, Personal and Institutional, Invited Speaker: Takeda; Financial Interests, Personal and Institutional, Invited Speaker: Teva; Financial Interests, Personal and Institutional, Invited Speaker: Viatris; Financial Interests, Personal and Institutional, Invited Speaker: Vifor Pharma; Financial Interests, Personal and Institutional, Research Grant: Accord; Financial Interests, Personal and Institutional, Research Grant: Amgen; Financial Interests, Personal and Institutional, Research Grant: Chugai; Financial Interests, Personal and Institutional, Research Grant: Hexal; Financial Interests, Personal and Institutional, Research Grant: Novartis; Financial Interests, Personal and Institutional, Research Grant: Takeda; Financial Interests, Personal and Institutional, Research Grant: Teva; Financial Interests, Personal and Institutional, Research Grant: Viatris; Financial Interests, Personal and Institutional, Research Grant: Vifor Pharma. S.F. Thompson: Financial Interests, Personal, Full or part-time Employment: Teva. M. Tian: Financial Interests, Personal, Full or part-time Employment: Teva. D. Meise: Financial Interests, Personal, Full or part-time Employment: Xcenda GmbH. J.S. Haas: Financial Interests, Personal, Full or part-time Employment: Xcenda GmbH. C. Maas: Financial Interests, Personal, Full or part-time Employment: Xcenda GmbH. S. Dimitrov: Financial Interests, Personal, Full or part-time Employment: Teva.